Global Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2020-2026

May 2020 | 150 pages | ID: GB0079D5A5EEEN
QYResearch

Abstracts

This report focuses on the global Drugs for Non-small Cell Lung Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Drugs for Non-small Cell Lung Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

• Bristol-Myers Squibb
• GlaxoSmithKline
• Menarini
• Sanofi
• Ziopharm Oncology
• Alchemia
• Amgen
• Apotex
• BioMarin Pharmaceutical
• CellAct Pharma
• Cerulean Pharma
• Cipla
• Cornerstone Pharmaceuticals
• Curis
• CytRx
• Eli Lilly
• Exelixis
• Fresenius Kabi
• Genentech
• Hikma Pharmaceuticals
• Hospira
• Intas Pharmaceuticals
• Karyopharm Therapeutics
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals

Market segment by Type, the product can be split into

• Radiofrequency Ablation (RFA)
• Radiation Therapy
• Chemotherapy
• Targeted Therapies
• Immunotherapy

Market segment by Application, split into

• Hospitals
• Clinics
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Drugs for Non-small Cell Lung Cancer status, future forecast, growth opportunity, key market and key players.
• To present the Drugs for Non-small Cell Lung Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Drugs for Non-small Cell Lung Cancer are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue
1.4 Market Analysis by Type
  1.4.1 Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Radiofrequency Ablation (RFA)
  1.4.3 Radiation Therapy
  1.4.4 Chemotherapy
  1.4.5 Targeted Therapies
  1.4.6 Immunotherapy
1.5 Market by Application
  1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinics
  1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Drugs for Non-small Cell Lung Cancer Market Perspective (2015-2026)
2.2 Drugs for Non-small Cell Lung Cancer Growth Trends by Regions
  2.2.1 Drugs for Non-small Cell Lung Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Drugs for Non-small Cell Lung Cancer Historic Market Share by Regions (2015-2020)
  2.2.3 Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Drugs for Non-small Cell Lung Cancer Market Growth Strategy
  2.3.6 Primary Interviews with Key Drugs for Non-small Cell Lung Cancer Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Market Size
  3.1.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Revenue (2015-2020)
  3.1.2 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Players (2015-2020)
  3.1.3 Global Drugs for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio
  3.2.1 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Drugs for Non-small Cell Lung Cancer Revenue in 2019
3.3 Drugs for Non-small Cell Lung Cancer Key Players Head office and Area Served
3.4 Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
3.5 Date of Enter into Drugs for Non-small Cell Lung Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Drugs for Non-small Cell Lung Cancer Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Type (2021-2026)

5 DRUGS FOR NON-SMALL CELL LUNG CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)
5.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
6.2 Drugs for Non-small Cell Lung Cancer Key Players in North America (2019-2020)
6.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
6.4 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
7.2 Drugs for Non-small Cell Lung Cancer Key Players in Europe (2019-2020)
7.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
7.4 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

8 CHINA

8.1 China Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
8.2 Drugs for Non-small Cell Lung Cancer Key Players in China (2019-2020)
8.3 China Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
8.4 China Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
9.2 Drugs for Non-small Cell Lung Cancer Key Players in Japan (2019-2020)
9.3 Japan Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
9.4 Japan Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
10.2 Drugs for Non-small Cell Lung Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

11 INDIA

11.1 India Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
11.2 Drugs for Non-small Cell Lung Cancer Key Players in India (2019-2020)
11.3 India Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
11.4 India Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
12.2 Drugs for Non-small Cell Lung Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
12.4 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Bristol-Myers Squibb
  13.1.1 Bristol-Myers Squibb Company Details
  13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  13.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Introduction
  13.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020))
  13.1.5 Bristol-Myers Squibb Recent Development
13.2 GlaxoSmithKline
  13.2.1 GlaxoSmithKline Company Details
  13.2.2 GlaxoSmithKline Business Overview and Its Total Revenue
  13.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Introduction
  13.2.4 GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.2.5 GlaxoSmithKline Recent Development
13.3 Menarini
  13.3.1 Menarini Company Details
  13.3.2 Menarini Business Overview and Its Total Revenue
  13.3.3 Menarini Drugs for Non-small Cell Lung Cancer Introduction
  13.3.4 Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.3.5 Menarini Recent Development
13.4 Sanofi
  13.4.1 Sanofi Company Details
  13.4.2 Sanofi Business Overview and Its Total Revenue
  13.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Introduction
  13.4.4 Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.4.5 Sanofi Recent Development
13.5 Ziopharm Oncology
  13.5.1 Ziopharm Oncology Company Details
  13.5.2 Ziopharm Oncology Business Overview and Its Total Revenue
  13.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Introduction
  13.5.4 Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.5.5 Ziopharm Oncology Recent Development
13.6 Alchemia
  13.6.1 Alchemia Company Details
  13.6.2 Alchemia Business Overview and Its Total Revenue
  13.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Introduction
  13.6.4 Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.6.5 Alchemia Recent Development
13.7 Amgen
  13.7.1 Amgen Company Details
  13.7.2 Amgen Business Overview and Its Total Revenue
  13.7.3 Amgen Drugs for Non-small Cell Lung Cancer Introduction
  13.7.4 Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.7.5 Amgen Recent Development
13.8 Apotex
  13.8.1 Apotex Company Details
  13.8.2 Apotex Business Overview and Its Total Revenue
  13.8.3 Apotex Drugs for Non-small Cell Lung Cancer Introduction
  13.8.4 Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.8.5 Apotex Recent Development
13.9 BioMarin Pharmaceutical
  13.9.1 BioMarin Pharmaceutical Company Details
  13.9.2 BioMarin Pharmaceutical Business Overview and Its Total Revenue
  13.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Introduction
  13.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.9.5 BioMarin Pharmaceutical Recent Development
13.10 CellAct Pharma
  13.10.1 CellAct Pharma Company Details
  13.10.2 CellAct Pharma Business Overview and Its Total Revenue
  13.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Introduction
  13.10.4 CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  13.10.5 CellAct Pharma Recent Development
13.11 Cerulean Pharma
  10.11.1 Cerulean Pharma Company Details
  10.11.2 Cerulean Pharma Business Overview and Its Total Revenue
  10.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Introduction
  10.11.4 Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.11.5 Cerulean Pharma Recent Development
13.12 Cipla
  10.12.1 Cipla Company Details
  10.12.2 Cipla Business Overview and Its Total Revenue
  10.12.3 Cipla Drugs for Non-small Cell Lung Cancer Introduction
  10.12.4 Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.12.5 Cipla Recent Development
13.13 Cornerstone Pharmaceuticals
  10.13.1 Cornerstone Pharmaceuticals Company Details
  10.13.2 Cornerstone Pharmaceuticals Business Overview and Its Total Revenue
  10.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  10.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.13.5 Cornerstone Pharmaceuticals Recent Development
13.14 Curis
  10.14.1 Curis Company Details
  10.14.2 Curis Business Overview and Its Total Revenue
  10.14.3 Curis Drugs for Non-small Cell Lung Cancer Introduction
  10.14.4 Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.14.5 Curis Recent Development
13.15 CytRx
  10.15.1 CytRx Company Details
  10.15.2 CytRx Business Overview and Its Total Revenue
  10.15.3 CytRx Drugs for Non-small Cell Lung Cancer Introduction
  10.15.4 CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.15.5 CytRx Recent Development
13.16 Eli Lilly
  10.16.1 Eli Lilly Company Details
  10.16.2 Eli Lilly Business Overview and Its Total Revenue
  10.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Introduction
  10.16.4 Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.16.5 Eli Lilly Recent Development
13.17 Exelixis
  10.17.1 Exelixis Company Details
  10.17.2 Exelixis Business Overview and Its Total Revenue
  10.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Introduction
  10.17.4 Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.17.5 Exelixis Recent Development
13.18 Fresenius Kabi
  10.18.1 Fresenius Kabi Company Details
  10.18.2 Fresenius Kabi Business Overview and Its Total Revenue
  10.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Introduction
  10.18.4 Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.18.5 Fresenius Kabi Recent Development
13.19 Genentech
  10.19.1 Genentech Company Details
  10.19.2 Genentech Business Overview and Its Total Revenue
  10.19.3 Genentech Drugs for Non-small Cell Lung Cancer Introduction
  10.19.4 Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.19.5 Genentech Recent Development
13.20 Hikma Pharmaceuticals
  10.20.1 Hikma Pharmaceuticals Company Details
  10.20.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
  10.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  10.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.20.5 Hikma Pharmaceuticals Recent Development
13.21 Hospira
  10.21.1 Hospira Company Details
  10.21.2 Hospira Business Overview and Its Total Revenue
  10.21.3 Hospira Drugs for Non-small Cell Lung Cancer Introduction
  10.21.4 Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.21.5 Hospira Recent Development
13.22 Intas Pharmaceuticals
  10.22.1 Intas Pharmaceuticals Company Details
  10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
  10.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  10.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.22.5 Intas Pharmaceuticals Recent Development
13.23 Karyopharm Therapeutics
  10.23.1 Karyopharm Therapeutics Company Details
  10.23.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
  10.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Introduction
  10.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.23.5 Karyopharm Therapeutics Recent Development
13.24 Kyowa Hakko Kirin
  10.24.1 Kyowa Hakko Kirin Company Details
  10.24.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue
  10.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Introduction
  10.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.24.5 Kyowa Hakko Kirin Recent Development
13.25 Ligand Pharmaceuticals
  10.25.1 Ligand Pharmaceuticals Company Details
  10.25.2 Ligand Pharmaceuticals Business Overview and Its Total Revenue
  10.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  10.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  10.25.5 Ligand Pharmaceuticals Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Drugs for Non-small Cell Lung Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue
Table 3. Ranking of Global Top Drugs for Non-small Cell Lung Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Radiofrequency Ablation (RFA)
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Chemotherapy
Table 8. Key Players of Targeted Therapies
Table 9. Key Players of Immunotherapy
Table 10. Global Drugs for Non-small Cell Lung Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2015-2020)
Table 14. Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Drugs for Non-small Cell Lung Cancer Market Growth Strategy
Table 20. Main Points Interviewed from Key Drugs for Non-small Cell Lung Cancer Players
Table 21. Global Drugs for Non-small Cell Lung Cancer Revenue by Players (2015-2020) (Million US$)
Table 22. Global Drugs for Non-small Cell Lung Cancer Market Share by Players (2015-2020)
Table 23. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2019)
Table 24. Global Drugs for Non-small Cell Lung Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
Table 27. Date of Enter into Drugs for Non-small Cell Lung Cancer Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 30. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Type (2015-2020)
Table 31. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)
Table 32. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Application (2015-2020)
Table 33. Global Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 34. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Application (2021-2026)
Table 35. North America Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 37. North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 38. North America Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 39. North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 40. North America Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 41. Europe Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 43. Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 45. Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 47. China Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 48. China Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 49. China Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 50. China Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 51. China Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 52. China Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 53. Japan Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 55. Japan Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 57. Japan Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 61. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 63. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 65. India Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 66. India Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 67. India Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 68. India Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 69. India Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 70. India Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)
Table 73. Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)
Table 75. Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Product
Table 80. Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Product
Table 85. GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 86. GlaxoSmithKline Recent Development
Table 87. Menarini Company Details
Table 88. Menarini Business Overview
Table 89. Menarini Product
Table 90. Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 91. Menarini Recent Development
Table 92. Sanofi Company Details
Table 93. Sanofi Business Overview
Table 94. Sanofi Product
Table 95. Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 96. Sanofi Recent Development
Table 97. Ziopharm Oncology Company Details
Table 98. Ziopharm Oncology Business Overview
Table 99. Ziopharm Oncology Product
Table 100. Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 101. Ziopharm Oncology Recent Development
Table 102. Alchemia Company Details
Table 103. Alchemia Business Overview
Table 104. Alchemia Product
Table 105. Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 106. Alchemia Recent Development
Table 107. Amgen Company Details
Table 108. Amgen Business Overview
Table 109. Amgen Product
Table 110. Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 111. Amgen Recent Development
Table 112. Apotex Business Overview
Table 113. Apotex Product
Table 114. Apotex Company Details
Table 115. Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 116. Apotex Recent Development
Table 117. BioMarin Pharmaceutical Company Details
Table 118. BioMarin Pharmaceutical Business Overview
Table 119. BioMarin Pharmaceutical Product
Table 120. BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 121. BioMarin Pharmaceutical Recent Development
Table 122. CellAct Pharma Company Details
Table 123. CellAct Pharma Business Overview
Table 124. CellAct Pharma Product
Table 125. CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 126. CellAct Pharma Recent Development
Table 127. Cerulean Pharma Company Details
Table 128. Cerulean Pharma Business Overview
Table 129. Cerulean Pharma Product
Table 130. Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 131. Cerulean Pharma Recent Development
Table 132. Cipla Company Details
Table 133. Cipla Business Overview
Table 134. Cipla Product
Table 135. Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 136. Cipla Recent Development
Table 137. Cornerstone Pharmaceuticals Company Details
Table 138. Cornerstone Pharmaceuticals Business Overview
Table 139. Cornerstone Pharmaceuticals Product
Table 140. Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 141. Cornerstone Pharmaceuticals Recent Development
Table 142. Curis Company Details
Table 143. Curis Business Overview
Table 144. Curis Product
Table 145. Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 146. Curis Recent Development
Table 147. CytRx Company Details
Table 148. CytRx Business Overview
Table 149. CytRx Product
Table 150. CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 151. CytRx Recent Development
Table 152. Eli Lilly Company Details
Table 153. Eli Lilly Business Overview
Table 154. Eli Lilly Product
Table 155. Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 156. Eli Lilly Recent Development
Table 157. Exelixis Company Details
Table 158. Exelixis Business Overview
Table 159. Exelixis Product
Table 160. Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 161. Exelixis Recent Development
Table 162. Fresenius Kabi Company Details
Table 163. Fresenius Kabi Business Overview
Table 164. Fresenius Kabi Product
Table 165. Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 166. Fresenius Kabi Recent Development
Table 167. Genentech Company Details
Table 168. Genentech Business Overview
Table 169. Genentech Product
Table 170. Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 171. Genentech Recent Development
Table 172. Hikma Pharmaceuticals Company Details
Table 173. Hikma Pharmaceuticals Business Overview
Table 174. Hikma Pharmaceuticals Product
Table 175. Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 176. Hikma Pharmaceuticals Recent Development
Table 177. Hospira Company Details
Table 178. Hospira Business Overview
Table 179. Hospira Product
Table 180. Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 181. Hospira Recent Development
Table 182. Intas Pharmaceuticals Company Details
Table 183. Intas Pharmaceuticals Business Overview
Table 184. Intas Pharmaceuticals Product
Table 185. Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 186. Intas Pharmaceuticals Recent Development
Table 187. Karyopharm Therapeutics Company Details
Table 188. Karyopharm Therapeutics Business Overview
Table 189. Karyopharm Therapeutics Product
Table 190. Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 191. Karyopharm Therapeutics Recent Development
Table 192. Kyowa Hakko Kirin Company Details
Table 193. Kyowa Hakko Kirin Business Overview
Table 194. Kyowa Hakko Kirin Product
Table 195. Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 196. Kyowa Hakko Kirin Recent Development
Table 197. Ligand Pharmaceuticals Company Details
Table 198. Ligand Pharmaceuticals Business Overview
Table 199. Ligand Pharmaceuticals Product
Table 200. Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US$)
Table 201. Ligand Pharmaceuticals Recent Development
Table 202. Research Programs/Design for This Report
Table 203. Key Data Information from Secondary Sources
Table 204. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Drugs for Non-small Cell Lung Cancer Market Share by Type: 2020 VS 2026
Figure 2. Radiofrequency Ablation (RFA) Features
Figure 3. Radiation Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapies Features
Figure 6. Immunotherapy Features
Figure 7. Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Other Case Studies
Figure 11. Drugs for Non-small Cell Lung Cancer Report Years Considered
Figure 12. Global Drugs for Non-small Cell Lung Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions: 2020 VS 2026
Figure 14. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Drugs for Non-small Cell Lung Cancer Market Share by Players in 2019
Figure 17. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Drugs for Non-small Cell Lung Cancer Revenue in 2019
Figure 19. North America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 28. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 30. Menarini Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Menarini Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 32. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Sanofi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 34. Ziopharm Oncology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 36. Alchemia Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Alchemia Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 38. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Amgen Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 40. Apotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Apotex Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 42. BioMarin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 44. CellAct Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. CellAct Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 46. Cerulean Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Cerulean Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 48. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Cipla Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 50. Cornerstone Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 52. Curis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Curis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 54. CytRx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. CytRx Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 56. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Eli Lilly Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 58. Exelixis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Exelixis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 60. Fresenius Kabi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Fresenius Kabi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 62. Genentech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Genentech Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 64. Hikma Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed